Serum matrix metalloproteinase-2 as a prognostic marker in advanced cutaneous melanoma.
The association was studied between serum concentration of matrix metalloproteinase-2 (MMP-2) and metastatic site, survival and disease progression in patients with advanced cutaneous melanoma. The patient population consisted of 50 patients who were treated with chemoimmunotherapy. The median baseline serum concentration of MMP-2 was 724 ng/ml (range 500-2,297 ng/ml). There were no significant differences in MMP-2 levels according to metastatic site. Baseline MMP-2 concentration did not have a prognostic value. The patients with levels below 800 ng/ml survived for 8.8 months and those with higher levels for 9.7 months. On serial measurements, median serum MMP-2 concentration at disease progression in 25 patients was significantly higher than before treatment. Only five samples at response were available, and the levels were not significantly different from baseline levels. In conclusion, serum MMP-2 is not a prognostic marker in advanced melanoma. It also appears to be of limited clinical value in monitoring.
Vuoristo
M S
MS
Department of Oncology, Tampere University and Tampere University Hospital, Finland. meri-sisko.vuoristo@tays.fi
Kellokumpu-Lehtinen
P
P
Parvinen
L M
LM
Hahka-Kemppinen
M
M
Korpela
M
M
Kumpulainen
E
E
Laine
S
S
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D018450:Disease Progression; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000097:blood* / Q000378:metabolism; D008545:Melanoma / Q000201:enzymology* / Q000473:pathology / Q000628:therapy; D008875:Middle Aged; D011379:Prognosis; D012680:Sensitivity and Specificity; D012878:Skin Neoplasms / Q000201:enzymology* / Q000473:pathology / Q000628:therapy; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D020778:Matrix Metalloproteinase 2